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Background
With a population of approximately 4.380 million peo-
ple and an estimated Lynch syndrome mutation preva-
lence of 1/531, there are an expected 8000 individuals
with Lynch syndrome in British Columbia. The Heredi-
tary Cancer Program (HCP) of the BC Cancer Agency
(BCCA) has provided clinical testing for Lynch syn-
drome since 2004 to patients across the province. Cur-
rently, there are approximately 100 patients with
confirmed Lynch syndrome mutations in the BCCA
database. Potential obstacles in ascertaining Lynch syn-
drome through a traditional clinic-based approach
include physician awareness of referral criteria, patient’s
lack of knowledge of cancer family history, patient com-
pliance, and availability of tumour tissue for testing.
Given these obstacles, a population based approach to
identifying Lynch syndrome through incident testing of
newly diagnosed colorectal cancers under age 50 by
microsatellite instability testing (MSI) was launched in
BC in June of 2008.
Methods
Chart review of a cohort of patients referred for genetic
counselling at the RCP during 2004-2006 and a cohort
of consecutive colorectal cancer cases referred directly
for MSI testing to the BCCA Genetics Laboratory (June
2008-June 2009). Mutation prevalence and clinicopatho-
logic characteristics will be compared between the two
groups. Clinical and demographic characteristics of the
groups will also be compared to non-referred cases diag-
nosed under 50 in the province.
Results
Our previous clinic-based results showed a 14.3% preva-
lence of Lynch syndrome mutations among the index
cases tested for whom results were available. 76% of
tumour results were microsatellite stable and intact for
MLH1 and MSH2 proteins. The sensitivity of the pro-
gram’s referral criteria was about 83.3% with an approxi-
mate confidence interval of 68.2%-96.8% and the
positive predictive value was about 38.3% with an
approximate confidence interval of 17.7%-60.0%. The
prevalence of Lynch syndrome mutations dropped to
3.2% among all patients referred for genetic counseling.
From July 2008 to July 2009, a total of 37 incident col-
orectal cases diagnosed under age 50 were referred
directly to the BC Cancer Agency’s cancer genetics lab.
73% were microsatellite stable while additional testing is
underway on the 10 MSI high cases. Further compari-
sons between the groups will be presented.
Conclusion
Aside from becoming increasingly important for prog-
nosis and predictive response to chemotherapy, popula-
tion based MSI analysis on newly diagnosed colorectal
cancer is expected to improve the rate of Lynch syn-
drome ascertainment in BC.
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